Y0001969
Etanercept
European Pharmacopoeia (EP) Reference Standard
grade
pharmaceutical primary standard
API family
etanercept
manufacturer/tradename
EDQM
application(s)
pharmaceutical
format
neat
Looking for similar products? Visit Product Comparison Guide
General description
Etanercept is one of the biologic disease-modifying anti-rheumatic drugs (DMARDs) used to treat rheumatoid arthritis (RA). It acts as a tumor necrosis factor (TNF) antagonist by binding with TNF cytokine or protein, thereby blocking its interaction with cell surface receptors. Thus, etanercept effectively relieves joint inflammation from RA and lowers the disease activity.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
This product is intended for laboratory tests as prescribed in the EP only. Established for use with the monograph(s): 2895.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
监管及禁止进口产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Development of a sensitive enzyme-linked immunosorbent assay for the measurement of biologically active etanercept in patients with ankylosing spondylitis
Wang L, et al.
Journal of Chromatography. B, Biomedical Applications, 1008, 219-224 (2016)
Etanercept
European Pharmacopoeia Commission and Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 4979-4983 (2021)
Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study
Daien CI, et al.
The Journal of Rheumatology, 39(8), 1533-1538 (2012)
Etanercept: An overview
Goffe B and Cather JC
Journal of the American Academy of Dermatology, 49(2), 105-111 (2003)
Characterization and application of a unique panel of monoclonal antibodies generated against etanercept
Detrez I, et al.
Journal of Immunology, 196(6), 2879-2884 (2016)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service